medicationNot FDA-approvedResearch chemicalNot approved by the FDA or EMA for any indication as of this writingOriginally developed for Parkinson's and Alzheimer's disease; that program was discontinued after weight loss was observed as a side effect, prompting obesity-focused trials
TesofensineBenefits, Dosage & Interactions
Tesofensine is an investigational compound initially developed for Alzheimer's disease, but later explored for its potential in weight management. It acts as a triple monoamine reuptake inhibitor, affecting serotonin, norepinephrine, and dopamine. It is typically taken in the morning. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
How much Tesofensine do people take?
0.25 mg, 0.5 mg, and 1.0 mg once-daily doses were compared to placebo in the randomized Astrup et al. dose-finding trial. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Tesofensine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
Not quantified in the cited human sources
Typical timing
in the morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Tesofensine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Tesofensine entry is written from. Each number matches an inline marker above.
- [1]Tesofensine and weight lossSommet A, Reynier-Rebuffel AM, Montastruc JL, Bagheri H · The Lancet · 2009 · Peer-reviewed · PMID 19249626
- [2]Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's diseaseAstrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM · Obesity (Silver Spring) · 2008 · Peer-reviewed · PMID 18356831
References & Evidence
Sources on this page that document Tesofensine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Tesofensine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Tesofensine is an investigational compound initially developed for Alzheimer's disease, but later explored for its potential in weight management. It acts as a triple monoamine reuptake inhibitor, affecting serotonin, norepinephrine, and dopamine. Research has primarily focused on its impact on appetite and satiety, with clinical trials examining its efficacy and safety profile. While not currently approved for medical use in most regions, studies have investigated its potential as an anti-obesity agent, particularly in individuals with a high body mass index (BMI). (Sources: PubChem, DrugBank)
What does the research say about Tesofensine?
Tap a section to expand.
Tesofensine exerts its pharmacological effects by inhibiting the reuptake of three key neurotransmitters: serotonin, norepinephrine, and dopamine. By blocking the reuptake transporters for these monoamines in the central nervous system, Tesofensine increases their concentrations in the synaptic cleft. This leads to enhanced neurotransmission, which is thought to influence various physiological processes related to appetite control, energy expenditure, and reward pathways.
* **Serotonin:** Increased serotonin levels are often associated with feelings of satiety and reduced food intake.
* **Norepinephrine:** Enhanced norepinephrine activity can contribute to increased energy expenditure and thermogenesis.
* **Dopamine:** Modulation of dopamine pathways, particularly in reward centers of the brain, may influence food cravings and hedonic eating.
The combined effect on these neurotransmitter systems is believed to contribute to Tesofensine's observed impact on weight loss. (Sources: DrugBank, PubChem)
Source for this section: Sources for How does Tesofensine work?: Jumps to this entry in the sources and references list at the end of the page.
Tesofensine has been primarily investigated for its potential to induce weight loss in individuals with obesity. Clinical studies have explored its effects on various parameters related to weight management:
* **Reduced Body Weight:** Trials have reported a dose-dependent reduction in body weight in participants treated with Tesofensine compared to placebo. This reduction is often attributed to a decrease in appetite and increased satiety.
* **Improved Body Composition:** Beyond weight loss, some studies have indicated improvements in body composition, including reductions in fat mass.
* **Appetite Suppression:** Participants often report a decrease in appetite and food cravings, which contributes to reduced caloric intake.
* **Enhanced Satiety:** The compound may promote feelings of fullness, leading to smaller meal sizes and less frequent eating occasions.
It is important to note that these potential benefits are derived from research studies and Tesofensine is not widely approved for medical use for weight loss. Individual responses may vary, and further research is ongoing. (Sources: Examine.com, DrugBank)
Clinical evidence for Tesofensine's efficacy in weight management comes primarily from randomized, placebo-controlled trials. Early studies in humans, specifically focusing on its primary indication for Alzheimer's, revealed weight loss as a significant side effect. This led to further investigation into its potential as an anti-obesity compound.
A key Phase 2 clinical trial (TALS study) demonstrated significant weight loss in obese patients treated with Tesofensine compared to placebo over a 24-week period. The study reported dose-dependent reductions in body weight, with the highest doses showing the most pronounced effects. Participants experienced reductions in hunger, increased satiety, and changes in eating behavior.
Further research, including subsequent Phase 3 trials, has continued to explore its long-term efficacy and safety. While some trials have shown promising results in achieving clinically meaningful weight loss, Tesofensine's development has faced regulatory hurdles in various regions, leading to its current status as an investigational drug. The collective evidence suggests Tesofensine's potential in weight management, but its clinical availability remains limited. (Sources: Cochrane Reviews of anti-obesity drugs, National Institutes of Health (NIH) clinical trial databases, Examine.com)
As with any compound affecting central nervous system neurotransmitters, Tesofensine can be associated with a range of side effects. Common side effects reported in clinical trials include:
* **Central Nervous System Effects:** Insomnia, dry mouth, headache, tremors, dizziness, and paresthesia (tingling sensation).
* **Cardiovascular Effects:** Increased heart rate and blood pressure have been observed in some individuals, particularly at higher doses.
* **Gastrointestinal Effects:** Nausea, constipation, and diarrhea.
* **Psychiatric Effects:** Anxiety, irritability, and mood changes have been reported.
* **Other:** Sweating, changes in taste perception.
Serious adverse events are less common but can include cardiovascular events. The incidence and severity of side effects are often dose-dependent. Given that Tesofensine is an investigational compound, the full spectrum of its long-term side effects may not be completely understood. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Tesofensine is an investigational compound, and as such, its use carries specific warnings. It affects multiple neurotransmitter systems, which can have broad physiological impacts.
* **Cardiovascular Risk:** Due to its potential to increase heart rate and blood pressure, Tesofensine should be used with extreme caution, or avoided, in individuals with pre-existing cardiovascular conditions, hypertension, or those at risk for cardiovascular events. Regular monitoring of heart rate and blood pressure is critical.
* **Psychiatric Conditions:** Individuals with a history of psychiatric disorders, particularly anxiety, depression, or mood disorders, should exercise caution as Tesofensine's effects on serotonin and dopamine could potentially exacerbate these conditions. Close monitoring for mood changes is advised.
* **Seizure Threshold:** There is a theoretical concern regarding Tesofensine's potential to lower the seizure threshold, although this has not been a primary finding in clinical trials. Individuals with a history of seizures should avoid its use.
* **Drug Interactions:** Tesofensine’s interaction with other medications, particularly those affecting monoamine systems, should be carefully considered to avoid potential adverse effects.
* **Not Approved for General Use:** It is crucial to remember that Tesofensine is not broadly approved for medical use in most regions, and its safety and efficacy profile continues to be studied. Its use should be under strict medical supervision if being accessed under a clinical trial or compassionate use program. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its pharmacological profile and potential side effects, Tesofensine is contraindicated in several circumstances:
* **Uncontrolled Hypertension:** Individuals with high blood pressure that is not adequately controlled by medication should not use Tesofensine due to its potential to further elevate blood pressure.
* **Significant Cardiovascular Disease:** A history of serious cardiovascular events such as myocardial infarction, stroke, or unstable angina, or significant arrhythmias, generally contraindicates the use of Tesofensine.
* **History of Seizures:** Individuals with a personal history of seizures or epilepsy should avoid Tesofensine due to theoretical concerns about lowering the seizure threshold.
* **Psychiatric Conditions:** Severe psychiatric disorders, including active depression with suicidal ideation, bipolar disorder, or severe anxiety disorders, may be contraindications, given Tesofensine's modulation of central neurotransmitters.
* **Glaucoma:** Narrow-angle glaucoma is a contraindication.
* **Hyperthyroidism:** Uncontrolled hyperthyroidism may be exacerbated by Tesofensine.
* **Use of MAOIs:** Concomitant use with monoamine oxidase inhibitors (MAOIs) is strictly contraindicated due to the risk of serotonin syndrome or hypertensive crisis.
* **Pregnancy and Breastfeeding:** Due to insufficient data on safety, Tesofensine is contraindicated during pregnancy and breastfeeding.
* **Known Hypersensitivity:** Individuals with a known allergy or hypersensitivity to Tesofensine or any of its components.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its effects on monoamine neurotransmitter systems, Tesofensine should not be mixed with several classes of medications, as this can lead to severe adverse reactions:
* **Monoamine Oxidase Inhibitors (MAOIs):** Concurrent use with MAOIs (e.g., phenelzine, tranylcypromine, selegiline) is strictly contraindicated. The combination can lead to a potentially fatal serotonin syndrome or hypertensive crisis due to excessive monoamine levels in the brain. A washout period of at least two weeks before or after MAOI use is typically recommended.
* **Serotonergic Drugs:** Co-administration with other drugs that increase serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, tramadol, and St. John's Wort, carries an increased risk of serotonin syndrome. Symptoms can include agitation, hallucinations, rapid heart rate, fever, and muscle rigidity.
* **Norepinephrine Reuptake Inhibitors (NRIs) and Stimulants:** Combining Tesofensine with other NRIs (e.g., atomoxetine) or stimulant medications (e.g., amphetamines, methylphenidate, cocaine, ecstasy) can potentiate cardiovascular effects (increased heart rate and blood pressure) and central nervous system stimulation.
* **Dopaminergic Drugs:** Interactions with dopaminergic agents may occur, requiring caution.
* **Adrenergic Agents:** Medications that affect adrenergic receptors (e.g., decongestants like pseudoephedrine, cold medicines) may increase cardiovascular risks when combined with Tesofensine.
* **Blood Pressure Medications:** Tesofensine may blunt the effects of antihypertensive medications, necessitating careful monitoring of blood pressure.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
In clinical studies, Tesofensine has typically been administered once daily. The 'morning' timing is commonly chosen to minimize the potential for sleep disturbances, as its central nervous system stimulating effects, particularly due to norepinephrine and dopamine reuptake inhibition, could interfere with sleep if taken later in the day. Given its long half-life of approximately 220 hours, a single daily dose is sufficient to maintain steady-state concentrations. Whether taken with or without food ('either') generally does not significantly impact its absorption or efficacy, though taking it with food might help mitigate any potential gastrointestinal upset for some individuals. Dosing is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Tesofensine?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Tesofensine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Tesofensine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Tesofensine
Tesofensine is a medication. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Tesofensine is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Tesofensine, it is typically taken in the morning. Always follow the specific dose your clinician or the product label prescribes.
Tesofensine carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Tesofensine comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Tesofensine is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Tesofensine with no sign-up.
There is no single answer for Tesofensine plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Tesofensine with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Tesofensine varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Tesofensine depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Tesofensine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
0.25 mg, 0.5 mg, and 1.0 mg once-daily doses were compared to placebo in the randomized Astrup et al. dose-finding trial. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Tesofensine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Tesofensine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam(opens PubMed in a new tab)Clin Pharmacokinet · 2009 · PMID 19705923 · https://pubmed.ncbi.nlm.nih.gov/19705923/
- 2.Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity(opens PubMed in a new tab)Curr Opin Investig Drugs · 2009 · PMID 19777399 · https://pubmed.ncbi.nlm.nih.gov/19777399/
- 3.Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease(opens PubMed in a new tab)Obesity (Silver Spring) · 2008 · PMID 18356831 · https://pubmed.ncbi.nlm.nih.gov/18356831/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 11370864(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/11370864
Verify at
Publisher search links for Tesofensine. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Tesofensine?
Plain-text summary, safe to quote verbatim:
Tesofensine is an investigational compound initially developed for Alzheimer's disease, but later explored for its potential in weight management. It acts as a triple monoamine reuptake inhibitor, affecting serotonin, norepinephrine, and dopamine. It is typically taken in the morning. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
Source: DoseRoutine — https://doseroutine.com/library/tesofensine
Tesofensine cheat sheet
DoseRoutine cheat sheet · Medication
Tesofensine
Tesofensine is an investigational compound initially developed for Alzheimer's disease, but later explored for its potential in weight management. It acts as a triple monoamine reuptake inhibitor, affecting serotonin, norepinephrine, and dopamine.
Evidence
Moderate
One published human randomized trial; results not yet replicated.
Studied range
0.25 mg, 0.5 mg, and 1.0 mg once-daily doses were compared to placebo in the randomized Astrup et al. dose-finding trial
Route
Oral
Frequency studied
Once daily
Half-life
Not quantified in the cited human sources
Timing
in the morning
Not FDA-approvedResearch chemicalNot approved by the FDA or EMA for any indication as of this writingOriginally developed for Parkinson's and Alzheimer's disease; that program was discontinued after weight loss was observed as a side effect, prompting obesity-focused trials
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/tesofensine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Tesofensine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/tesofensine
What compounds are similar to Tesofensine?
Others in the medication category or studied for the same goals.